Allogene Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
This Form 8-K, dated July 30, 2021 and signed August 2, 2021, reports changes to Allogene Therapeutics’ board of directors under Item 5.02. It is not a periodic financial report and does not provide results for a reporting period.
Board changes and compensation
- The board increased its authorized size from nine to eleven directors.
- Elizabeth Barrett was appointed as a Class I director, with a term expiring at the 2022 annual meeting.
- Vicki Sato, Ph.D. was appointed as a Class II director, with a term expiring at the 2023 annual meeting.
- Each director will receive an annual cash retainer of $40,000.
- Ms. Barrett received an option award with an aggregate grant-date value of $850,000, vesting monthly over three years.
- Dr. Sato received an option award with an aggregate grant-date value of $425,000, vesting monthly over three years, and a restricted stock unit award with an aggregate grant-date value of $425,000, vesting in three equal annual installments.
- Equity awards described in the filing fully vest upon a qualifying change in control.
- Both directors entered into the company’s standard indemnification agreement.
Financial metrics and liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics.
Material changes, outlook, and risks
The material change reported is the expansion of the board and appointment of two directors. The filing contains no management outlook, business guidance, risk update, contingency, or unusual operating item. The disclosed director compensation will result in equity awards and related compensation expense, but the filing does not quantify the accounting expense or dilution impact.
Key facts for investors to verify
- Confirm the directors’ backgrounds, committee assignments, and expected contribution to governance and strategy.
- Review the applicable non-employee director compensation policy and the detailed terms of the equity awards.
- Assess the potential dilution and future stock-based compensation expense associated with the awards.
- Review subsequent filings for any changes in board composition, director compensation, or equity award terms.